Teva Pharmaceuticals (NYSE:TEVA) has inked a non-exclusive licensing deal to use ProBioGen‘s human artificial lymph node technology in the preclinical testing of the pharma company’s drug candidates.
ProBioGen, a contract developer and manufacturer based in Berlin, designed its 3D micro-organoid model for companies to use to predict the reactions that their drugs will provoke in the human immune system.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva inks deal to test drugs with ProBioGen’s artificial lymph node tech appeared first on MassDevice.
from MassDevice http://ift.tt/2nPXwGB
Cap comentari:
Publica un comentari a l'entrada